Jounce Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

You can watch JNCE and buy or sell other stocks, ETFs, and their options commission-free!

About JNCE

Jounce Therapeutics, Inc. is a clinical stage immunotherapy company, which engages in developing treatments for cancer. It also provides novel cancer immunotherapies to attack tumors. 

CEO
Kevin C. Tang
CEOKevin C. Tang
Employees
Employees
Headquarters
Cambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded
2013
Founded2013
Employees
Employees

JNCE Key Statistics

Market cap
98.95M
Market cap98.95M
Price-Earnings ratio
-1.91
Price-Earnings ratio-1.91
Dividend yield
Dividend yield
Average volume
2.01M
Average volume2.01M
High today
High today
Low today
Low today
Open price
Open price
Volume
0.00
Volume0.00
52 Week high
$5.87
52 Week high$5.87
52 Week low
$0.5773
52 Week low$0.5773

Stock Snapshot

Jounce Therapeutics(JNCE) stock is priced at $1.88, giving the company a market capitalization of 98.95M. It carries a P/E multiple of -1.91.

On 2026-02-11, Jounce Therapeutics(JNCE) shares started trading at —, with intraday highs of — and lows of —.

Trading activity shows a volume of 0, compared to an average daily volume of 2.01M.

The stock's 52-week range extends from a low of $0.58 to a high of $5.87.

The stock's 52-week range extends from a low of $0.58 to a high of $5.87.

People also own

Based on the portfolios of people who own JNCE. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.